The role of ferroptosis in prostate cancer: a novel therapeutic strategy

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

PubMed  Google Scholar 

Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1–14.

CAS  PubMed  Article  Google Scholar 

Lorkowski J, Grzegorowska O, Kozień MS, Kotela I. Effects of breast and prostate cancer metastases on lumbar spine biomechanics: rapid in silico evaluation. Adv Exp Med Biol. 2018;1096:31–39.

CAS  PubMed  Article  Google Scholar 

Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 2016;46:484–90.

PubMed  Article  Google Scholar 

Darwish OM, Raj GV. Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol. 2012;2:48.

PubMed  PubMed Central  Article  Google Scholar 

Cheng L, MacLennan GT, Bostwick DG. Urologic surgical pathology. 4rth ed. Philadelphia, PA: Elsevier; 2019.

Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323:149–63.

PubMed  PubMed Central  Article  Google Scholar 

Myint ZW, Kunos CA. Bone fracture incidence after androgen deprivation therapy-investigational agents: results from cancer therapy evaluation program-sponsored early phase clinical trials 2006-2013. Front Oncol. 2020;10:1125.

PubMed  PubMed Central  Article  Google Scholar 

Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E, et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology. 2013;1:583–9.

CAS  PubMed  Article  Google Scholar 

Curtis KK, Pruthi RK, Fonseca R, Gornet MK. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer. Urology. 2007;70:811.e5–8.

Article  Google Scholar 

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J, et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol Cell. 2021;81:355–369.e10.

CAS  PubMed  Article  Google Scholar 

Hambright WS, Fonseca RS, Chen L, Na R, Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017;12:8–17.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26:2284–99.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, et al. Correction to: Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ. 2020;27:1447.

PubMed  Article  Google Scholar 

Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81:1583–94.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017;36:4089–99.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bridges RJ, Natale NR, Patel SA. System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharm. 2012;165:20–34.

CAS  Article  Google Scholar 

Pfeiffer R, Spindler B, Loffing J, Skelly PJ, Shoemaker CB, Verrey F. Functional heterodimeric amino acid transporters lacking cysteine residues involved in disulfide bond. FEBS Lett. 1998;439:157–62.

CAS  PubMed  Article  Google Scholar 

Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79:1913–24.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014;3:e02523.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Patel D, Kharkar PS, Gandhi NS, Kaur E, Dutt S, Nandave M. Novel analogs of sulfasalazine as system xc- antiporter inhibitors: Insights from the molecular modeling studies. Drug Dev Res. 2019;80:758–77.

CAS  PubMed  Article  Google Scholar 

Genchi G, Sinicropi MS, Lauria G, Carocci A, Catalano A. The effects of cadmium toxicity. Int J Environ Res Public Health. 2020;17:3782.

CAS  PubMed Central  Article  Google Scholar 

Zhang Y, Guo S, Wang S, Li X, Hou D, Li H, et al. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling. Ecotoxicol Environ Saf. 2021;220:112376.

CAS  PubMed  Article  Google Scholar 

Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015;356:197–203.

CAS  PubMed  Article  Google Scholar 

Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57–62.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhou X, Zou L, Chen W, Yang T, Luo J, Wu K, et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharm Res. 2021;164:105305.

CAS  Article  Google Scholar 

Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019;2019:5080843.

PubMed  PubMed Central  Google Scholar 

Cozza G, Rossetto M, Bosello-Travain V, Maiorino M, Roveri A, Toppo S, et al. Glutathione peroxidase 4-catalyzed reduction of lipid hydroperoxides in membranes: The polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center. Free Radic Biol Med. 2017;112:1–11.

CAS  PubMed  Article  Google Scholar 

He S, Zhang M, Ye Y, Zhuang J, Ma X, Song Y, et al. ChaC glutathione specific γ-glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis. Exp Ther Med. 2021;22:997.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jelinek A, Heyder L, Daude M, Plessner M, Krippner S, Grosse R, et al. Mitochondrial rescue prevents glutathione peroxidase-dependent ferroptosis. Free Radic Biol Med. 2018;117:45–57.

CAS  PubMed  Article  Google Scholar 

Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Xu P, Wang Y, Deng Z, Tan Z, Pei X. MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression. Oncol Lett. 2022;23:67.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li R, Jia Z, Trush MA. Defining ROS in biology and medicine. React Oxyg Species. 2016;1:9–21.

Google Scholar 

He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem. 2017;44:532–53.

PubMed  Article  Google Scholar 

Zhao M, Wang Y, Li L, Liu S, Wang C, Yuan Y, et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics. 2021;11:1845–63.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Arra M, Swarnkar G, Ke K, Otero JE, Ying J, Duan X, et al. LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis. Nat Commun. 2020;11:3427.

PubMed  PubMed Central  Article  CAS  Google Scholar 

留言 (0)

沒有登入
gif